Dystonia - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dystonia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dystonia - Pipeline Review, H1 2016', provides an overview of the Dystonia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dystonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dystonia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dystonia
- The report reviews pipeline therapeutics for Dystonia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dystonia therapeutics and enlists all their major and minor projects
- The report assesses Dystonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dystonia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dystonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dystonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dystonia Overview 6
Therapeutics Development 7
Pipeline Products for Dystonia - Overview 7
Pipeline Products for Dystonia - Comparative Analysis 8
Dystonia - Therapeutics under Development by Companies 9
Dystonia - Therapeutics under Investigation by Universities/Institutes 11
Dystonia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Dystonia - Products under Development by Companies 15
Dystonia - Products under Investigation by Universities/Institutes 16
Dystonia - Companies Involved in Therapeutics Development 17
Addex Therapeutics Ltd 17
Advicenne Pharma 18
EpiVax, Inc. 19
Ipsen S.A. 20
Revance Therapeutics, Inc. 21
Dystonia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
abobotulinumtoxin A - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
abobotulinumtoxin A next generation - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dipraglurant ER - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
onabotulinumtoxin A - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RT-002 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tetrabenazine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Dystonia - Recent Pipeline Updates 39
Dystonia - Dormant Projects 43
Dystonia - Product Development Milestones 44
Featured News & Press Releases 44
Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 44
Oct 29, 2015: Revance Reports Positive 6-Month Duration in BELMONT Study 45
Sep 29, 2015: Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia 47
Feb 05, 2014: Ipsen announces clinical results of Dysport Next Generation and its intent to file the first ready-to-use liquid toxin A in Europe and ROW 47
Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved Botox 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Dystonia, H1 2016 7
Number of Products under Development for Dystonia - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Dystonia - Pipeline by Addex Therapeutics Ltd, H1 2016 17
Dystonia - Pipeline by Advicenne Pharma, H1 2016 18
Dystonia - Pipeline by EpiVax, Inc., H1 2016 19
Dystonia - Pipeline by Ipsen S.A., H1 2016 20
Dystonia - Pipeline by Revance Therapeutics, Inc., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Dystonia Therapeutics - Recent Pipeline Updates, H1 2016 39
Dystonia - Dormant Projects, H1 2016 43